Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 27, 2007 Tom Taulli	A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth.
Bio-IT World October 2005 Mark D. Uehling	Phase Forward Acquires Lincoln Technologies As the most intriguing clinical trial technology deal of the year, the acquisition demonstrates both Phase Forward's financial resources and the appeal of Lincoln Technologies' Java- and Web-based tools for the analysis and visualization of drug safety.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
Fast Company December 2009 Erica Westly	The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness.
The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
The Motley Fool April 27, 2005 Charly Travers	Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool June 16, 2010 Brian Orelli	Double-Digit Rise on Doubling Its Cash Neurocrine Biosciences is seeing a nice boost to its stock price today -- some 14% -- after Abbott Labs agreed to license its endometriosis treatment, elagolix, and any future follow-on products.
Chemistry World September 4, 2015 Matthew Gunther	Novartis to buy experimental MS drug from GSK in $1bn deal Currently in Phase II trials, the injectable drug ofatumumab, promoted under the brand name Arzerra, is an antibody that attacks specific proteins in the immune system.
The Motley Fool December 12, 2007 Brian Orelli	What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010.
The Motley Fool June 12, 2009 Brian Orelli	Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side.
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool June 21, 2004 Brian Gorman	Clinical Trials Controversy The American Medical Association wants more transparency in clinical trials, a proposal that may leave drug companies and investors with mixed feelings.
The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool December 27, 2010 Brian Orelli	Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline.
The Motley Fool March 13, 2007 Brian Lawler	Panacos Springs Ahead Panacos advances its lead drug program.
The Motley Fool August 22, 2006 Brian Lawler	Sticking With Myriad Genetics The potential for growth in one division offsets the risk in its trials for an Alzheimer's drug. For less risk-adverse investors, the 5% pullback in Myriad's shares Tuesday might offer a great chance to invest in this well-run company.
Popular Mechanics November 19, 2009 Joe P. Hasler	Top 6 North American Meteor Showers You Don't Want to Miss A list of upcoming meteor spectacles in the sky.
The Motley Fool September 28, 2006 Brian Lawler	Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens.
The Motley Fool May 22, 2007 Mike Havrilla	Coley Gets a Cold Reception The market cares little for this drug developer's promising prospects, but some investors like this pharma at it current $230 million market cap, given the company's strong partnerships.
The Motley Fool February 17, 2010 Brian Orelli	$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%.
The Motley Fool December 27, 2006 Brian Lawler	Telik Falls Short Shares of another biopharma fall after disappointing clinical trial results.
The Motley Fool November 30, 2007 Brian Orelli	Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way.
The Motley Fool November 30, 2011 Brian Orelli	Up Big With Room to Run Lofty hep C valuations are par for the course.
The Motley Fool March 10, 2009 Brian Orelli	So Much Potential, So Little Growth In its quest to become the Johnson & Johnson of China, this purveyor of traditional Chinese medicine has been growing through acquisitions, but has paid for them through dilutive stock offerings.
The Motley Fool July 10, 2009 Brian Orelli	Vertex Pulls a Wimpy After four follow-on stock offerings in the last three years, Vertex Pharmaceuticals finally has a plan to raise some cash that won't dilute its shareholders.
The Motley Fool September 25, 2007 Brian Orelli	No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes.
Chemistry World January 25, 2013 Rajesh Parishwad	Indian supreme court's anger over unregulated clinical trials The fledgling clinical trials industry in India has been hit by recent revelations of a lack of regulation. Now, the country's supreme court has criticized the body that oversees clinical trials for its inaction in the face of these unethical practices.
The Motley Fool April 12, 2004 Charly Travers	Bargain Hunting in Big Biotech MedImmune's recent FluMist troubles may have created a buying opportunity for long-term investors.
The Motley Fool April 29, 2004 Brian Gorman	Merck, Bristol-Myers Team Up Their agreement to commercialize a diabetes drug reflects intense sales competition in the industry.
The Motley Fool November 3, 2011 Sean Williams	Bash My Stock: Ariad Pharmaceuticals For those of you who've wondered what's wrong with your stock...
The Motley Fool December 4, 2006 Brian Lawler	Success for Dynavax Solid results from the first of three phase III trials cause the biopharmaceutical Dynavax's shares to rise.
The Motley Fool July 20, 2007 Brian Orelli	Arena Keeps Burning the Cash The pipeline drugs being developed by Arena Pharmaceuticals hold promise, but it will be a while before, or if, the company shows a profit.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
Chemistry World November 3, 2015 Phillip Broadwith	Bristol-Myers Squibb to buy Cardioxyl for heart drug The deal gives BMS full rights to develop CXL-1427, an experimental drug for acute decompensated heart failure, currently in Phase II clinical trials.
The Motley Fool May 5, 2009 Robert Steyer	Sanofi-Aventis' To-Do List The French drugmaker seeks acquisitions to reinforce and expand its business geographically and scientifically.
The Motley Fool May 16, 2007 Mike Havrilla	Waiting on Memory Pharmaceuticals The small-cap biotech is testing a treatment for Alzheimer's, but investors should stand by.
The Motley Fool April 30, 2008 Brian Lawler	Alexza Advances 2 More Drugs The pharmaceutical company's compounds keep zipping through clinical trials.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
Chemistry World October 15, 2013 Dinsa Sachan	Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
Chemistry World September 25, 2013 Phillip Broadwith	Nanobody inflammation drug attracts Abbvie Belgian biotech firm Ablynx has agreed a global licensing deal with Abbvie for its nanobody drug candidate ALX-0061.
The Motley Fool October 1, 2009 Brian Orelli	Geez, Lighten Up, Mr. Market! Investors dish out undue punishment to Onyx's stock.
The Motley Fool January 12, 2005 Charly Travers	Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity.
The Motley Fool May 9, 2007 Mike Havrilla	Scintillating Synta Patient investors should peek at this pharma's promising pipeline.
Bio-IT World March 2006 Kevin Davies	Clinical Data Launches Landmark Trial Clinical Data has launched a Phase III clinical trial for the depression drug vilazodone and will concurrently develop a diagnostic test. The study could prove to be a landmark event in pharmacogenomic medicine.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool December 19, 2008 Brian Orelli	Open-Label Bites Drug Duo Pfizer and Celldex have to make the best of a bad situation.